Patent information
IP India · live recordAbstract
The present disclosure relates generally to novel molecules compositions and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens
Applicants
1Inventors
8Specification
Show full textCollapse
TREATMENTS FOR RESISTANT ACNE RELATED APPLICATIONS [0001} This application claims benefit priority of of Indian Patent Application No. 269/DEL/2014, filed January 29, 2014 and No. 3247/DEL/2014, filed November 10, 2014, the content of both applications is incorporated herein by reference in their entirety. FIELD OF THE INVENTION
[0002] The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic-tolerant pathogens. BACKGROUND OF THE INVENTION
[0003] Acne vulgaris is a skin condition that affects over 85% of all people. Acne is a term for a medical condition of plugged pores typically occurring on the face, neck, and upper torso. Following are four primary factors that are currently known to contribute to the formation of acne vulgaris; (1) increased sebum output resulting in oily, greasy skin; (2) increased bacterial activity, normally due to an overabundance of Propionibacterium acnes bacteria; (3) plugging (hypercornifi cation) of the follicle or pilosebaceous duct; and (4) and inflammation. The plugged pores result in blackheads, whiteheads, pimples or deeper lumps such as cysts or nodules. Severe cases of acne can result in permanent scarring or disfiguring.
[0004] Though acne vulgaris is multifactorial, a commensal skin bacteria ( . acnes) plays a major role in the formation of acne lesion. It is an infection of pilosebacious glands, oil glands in the skin. In most cases sudden breakouts of acne can be correlated with sudden increased production of sebum in the affected individual. During adolescence androgen hormones play a crucial role. It leads to overproduction of sebum by the pilosebaceous gland. The situation gets further accentuated by irregular shedding of dead skin from lining of hair follicles. As the dead skin cells clump together in the oily environment, they can form plugs which block the pores of the hair follicles. A pore clogged by the shedding skin is referred to as a comedo.
[0005] This creates a very conducive anaerobic condition for P. acnes bacteria to grow. Hyperproliferation of P. acnes leads to destruction of follicular walls and it sends a danger signal to the host immune system. P. acnes may trigger an innate immune reaction both in very early (microcomedogenic) and in late (inflammatory) acne lesions via the activation of Toll like receptors 2 (TLR2) on inante immune cells. TLR activation ultimately triggers the expression various cytokines (like IL-6, 1L-8, L- 2, IL-17 etc) and chemokines that stimulate recruitment of other host immune cells [Jeremy et al, 2003; Thibout et al, 2014]. Acne lesions range in severity from blackheads, whiteheads and pimples to more serious lesions such as deeper lumps, cysts and nodules.
[0006] Although various over-the-counter products are commercially available to counteract acne condition, such as anti-acne agents for topical use, including salicylic acid; sulfur; lactic acid; glycolic acid; pyruvic acid; urea; resorcinol; N-acetylcysteine; retinoic acid; isotretinoin; tretinoin; adapalene; tazoretene; antibacterial s such as clindamycin, tetracyclines, and erythromycin; vitamins such as folic acid and nicotinamide; minerals such as zinc; benzoyl peroxide; octopirox; triclosan; azeiaic acid; phenoxyethanol; phenoxypropanol; and flavinoids, these agents tend to lack in potential to mitigate the acne condition and may have negative side effects when devised in conventional topical formulations. A key challenge that has limited the use of topical formulations is the absence of formulations with the desired physicochemical properties and high drug loading, which maintains a concentration significantly higher tha the MIC at the site of application by facilitating the right degree of penetration over time but with minimal systemic exposure. A formulation that addresses these unmet needs can be a significant advance in the treatment of acne.
[0007] Furthermore, as articulated in [Taglietti et al, 2008], when it comes to the delivery of a drug to a specific site, topical formulations that are efficacious are probably among the most challenging products to develop. Once the product is applied on the skin, a complex interaction occurs between the formulation, the active compounds, and the skin itself. The penetration of the active compound(s) into the skin follows Pick's first law of diffusion, which describes the transfer rate of solutes as a function of the concentration of the various ingredients, the size of the treatment surface area, and the permeability of the skin. However, the skin's permeability can be influenced by many factors, such as the drying, moisturizing, or occluding effects of the excipients in the formulation, which, in combination, can modulate the release of the product at the treatment site. In acne, the site of action is inside the pilosebaceous unit and, therefore, an efficacious anti-acne formulation should facilitate the penetration of the active compound(s) into this extremely lipophilic environment. An effective topical formulation therefore needs to provide a stable chemical environment in a suitable dispensing container in order to accommodate multiple compounds that may have different, if not incompatible, physicochemical characteristics [Tagleitti et a , 2008]. Once applied, a topical formulation must interact with the skin environment, which can influence the rate of the release of the compound(s) in order to achieve adequate skin absorption, and exert additional physical effects on the skin, such as drying, occluding, or moisturizing [Tagleitti et a , 2008]. For example, even if an active agent is very potent, and is effective via a systemic route, in the case of topical administration can behave completely differently, i.e. if the desired concentration is not reached in the pilosebaceous (or skin) unit, it will not serve as an effective anti-acne therapy. Similarly, a molecule or drug can behave entirely differently if formulated with different compositions, which we demonstrate later in an example. Similarly, two molecule or active agents may behave entirely differently in the same formulation or composition. Therefore, every new molecule that needs to be formulated for topical skin application poses a novel and independent challenge as it is impossible to predict which composition and ratio of active and excipients will provide the desired efficacy benefit.
[0008] Furthermore, an emerging condition is the evolution of strains of P. acnes, which do not respond to theantibiotic agents such as clindamycin, tetracyclines and erythromycincurrently approved for the treatment of acne.While the earlier dogmawas that antibiotics failure arises due to selection of 'resistant' strains, i.e. a mutation resulting in alteration of the target of the antibioticrendering it ineffective, emerging evidence suggests that antibiotic failure is more complex than this simple understanding. The assumption was that if resistance develops, i.e. the target of an antibiotic is altered, it is possible to treat the condition by changing to an alternative antibiotic, the target of which is still intact in the bacteria. However, recent knowledge has rendered this assumption as false. For example, Regoes et al, 2004 demonstrates that even in the absence of any resistance, a subset of bacteria can just exhibit tolerance to an antibiotic, i.e. not undergo lysis. This could arise due to physiological (metabolic) and morphological changes observed in bacteria exposed to antibiotics.For example, in a study published in Science, [Miller et al, 2004] showed that a transient induction of SOS response by ampicillin can protect E. coli against the bactericidal effects of ampicillin Regoes et al, 2004 suggested that tolerance mechanisms could cross over between some antibiotics, i.e. Antibiotic A might be rendered ineffective due to development of resistance, but it is possible that Antibiotic B, which has an entirely different target/mechanism of action, and is shown to be active in a different or sensitive bacterial strain, may also be rendered ineffective in the resistant strain due to shared tolerance mechanisms. Indeed, massive changes in gene expression leading to alteration in the syntheses of proteins of metabolic and stress response pathways and cell division during exposure of E. coli to ampicillin and ofloxacin have been observed, and a number of these alterations in the gene expression levels were shared between bacteria exposed to ampicillin and ofloxacin, suggesting a bacteria not respondingto ampicillin may not respond to ofloxacin although both agents have different targets. We saw a similar observation in screening a library of antibiotics against different strains of P. acnes that are sensitive or non-responsive to clindamycin (a lincosamide). As shown in Fig. 1A, the strain of P. c on responsive to clindamycin also showed increased survival capability in the presence of roxithromycin (a nac iide) which targets a different site from clindamycin. [Keren et al, 2004]. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J . Bacteriol. 186 8172-8 180) suggested that random fluctuations in gene expression are responsible for the formation of specialized persister cells. As argued by Regoes et al, 2004, phenotypic tolerance to antibiotic could actua y prevent clearance. As a result, while there remains a need in the art for compositions, formulations and methods for treating acnethat is not responding to the currently used agents, especially clindamycin-, minocydine-, erythromycin-, and/or doxycycline, the probability of tolerance makes itimprobable to predict a drug that may work against P. acnes.
[0009] Furthermore, it is increasingly becoming evident that subtle changes in chemical structure of a molecule can dramatically change activity of the molecules against target protein. For example erythromycin (a macrolide) and clindamycinbind to similar 50S ribosomal unit but crystal structure [Schulzen et al, 200 showed different mode of binding between the agents and amino acid residues present in SOS ribosomal sub-unit. There are known bacterial strains of P. acnes that are resistant to clindamycin but can be either non-responsive or susceptible to erythromycinand vice versa. Interestingly, telithromycin, which is a semisynthetic derivative of erythromycin works well in a bacterial strain that is resistant to both erythromycin and clindamycin [Beitru et al, 2003] Similarly, in another example, the introduction of 8-chloro group dramatically enhanced the potency of moxifioxacin but a similar change in gatifloxacin had no effect agains S aureus, S. pneumonia, and E. coli. Additionally, molecules of the same class can have different affinity for the same protein target but in different bacteria. For example it has been found that both besifloxacin and moxifioxacin effectively bind to DNA gyrase than ciprofloxacin in S. aureus. n contrary ciprofloxacin binding towards DNA gyrase is more effective in E.coli than moxifioxacin or besifloxacin. Similarly, besifloxacin is found to be best effective molecule against S. pneumonia followed by moxifioxacin and ciprofloxacin. [Cambau et al, 2009]. t is therefore not possible to predict the activity of a moleculeagainst a bacteria or microbe based on its similarity in structure another drug that shows activity against the same microbe or a different microbe, even though they might have similar mechanisms of action. Indeed, as shown in Figure. 1, we observed that molecules that were verisimilar in structure had completely distinct activity against P. acnes, i.e. where one was inactive the other was very potent against both ciindamycin-susceptible and -non-resistant P. acnes (Fig. 1 A and IB). In another example, which we discuss later, we observed a nonlincosamide molecule that was very effective in a P. acnes strain resistant to clindamycin but not active in a ciindamycin-sensitive P. acnes (Fig. 1A and IB). The identification of an effective drug that works against both sensitive as well as clindamycin-, minocycline-, erythromycin-, or doxyeycline-nonresponder P. acnes therefore emerges through serendipity during systematic screening in P. acnes.
[0010] Furthermore, while an emerging problem is the development of resistant strains of microbes that are not responding to antimicrobial compounds and compositions well known in the art, there remains a need in the art for a more effective antibiotic that not only works against resistant microbes but also reduces the risk of development of resistance by the microbes to this new antibiotic. Thus molecules that are efficacious antibiotics and also 'prevent' or reduce the development of resistance can be a major advancement in the treatment of microbial diseases. [00 ] The inflammatory character of acne has been correlated with the host immune response targeting Propionihacterium acnes. In vitro studies demonstrate that P. acnes whole cells or cell fractions stimulate cytokine and matrix metalloproteinase release from immune cells, keratinocytes, and sebocytes [Kim et al, 2002; Liu et al., 2005: Nagy et al., 2006; Lee et al., 2010] Though P. acnes are ong been present in the follicular area , they come in direct contact with immune cells in dermis on y after follicular rupture, The innate immune system recognizes P. acnes via TLR2 [Kim et al., 2002], leading to the secretion of inflammatory cytokines, including IL-6.IL-8 L-12 etc. Follicular rupture happens very late in the disease process. But there are multiple evidences which suggest that the adaptive immune response also has a significant role in the inflammation observed even in early stages of acne, resulting from the recruitment of activated T helper 1 (Thl) lymphocytes to early acne lesions [Mouser et al., 2003].A potential treatment of acne therefore needs to resolve inflammation, and should be able to target these inflammatory pathways.
[0012] An ideal treatment for acne therefore needmolecules that can work at two or more targets. Molecules that work against both antibiotic-sensitive as well as clindamycin-, minocycline-, erythromycin- and doxycycHne-tolerant or nonresponsivestrains of P. acnesand ca additionally inhibit the P. c« , -activated inflammatory mediator/s, or molecules that target two or more cellular targets in these microbes while additionally exerting an inhibitory effect on the P. acnesactivated inflammatory mediator/s, and is formulated in an optimal formulation that enables the desired concentration of the active agent on the skin or pilosebaceous region following topical application can emerge as a powerful strategy for the treatment of acne. SUMMARY DART
[0013] A series of novel DART (Dual Action Rational Therapeutics) molecules were designed and synthesized for treatment of bacterial infections caused by both susceptible and resistant gram positive and gram negative bacteria and specially for curing acne and different skin and skin structure infections and additionally prevent the development of resistance. DART molecules can mount its activity through two distinct mechanisms of action in a microbe (such as a bacteria), and create less chance in mutation development at both target sites in the bacteria. Additionally, it can also act at the host level by modulating the immune response, such as altering the levels of inflammatory cytokines.
[0014] The design of DART comprises of two active domains. The two active domains can be selected from different families, for example,P-lactam, b-lactam derivatives, 2- and 4-quinolones, quinolones having halogenated atom specially fluorine atom attached at C-6 or C-7 position of the central ring system, fluoroquinolone with halogenated atom specially chlorine atom attached at C-8 position of the central ring system, tetracycline, oxazolidinone, hydroxypyridones, derivatives of hydroxypyridones, pieuromutifin, azoles, nitroimidazoles, monoxycarbolic acid class, fusidic acid, sulfonamide, sulfonamide derivatives, retinoids, different fatty acids (saturated, unsaturated), propylene glycol and glycerol derivatives of different fatty acids and a strategic combination from each of the families. The design was made strategically by arranging the two active domains in the right steric arrangement for both the active domains to maintain their function against bacteria or fungus. Overall these molecules possess faster bacterial killing with reduction in inflammation and activity against resistant pathogens. These molecules also show a lower risk of development of resistance.
[0015] In some embodiments, the DART molecule has at least two chemical domains. Each of said chemical domains binds to a distinct or different active site in a target cell. In a preferred embodiment, a third chemical domain may be present. In a further preferred embodiment, said two chemical domains may be bound together through a said third domain. In some embodiments, the DART molecule has at least two distinct or different anti-bacterial mechanisms of action. In some embodiments, the DART molecule has at least two distinct or different anti-acne mechanisms of action. Without limitations, the DARTs can act on the same target or on different targets, for example, the bacteria and the host. In some embodiments, the DART acts on at least two different targets. In some embodiments, at least one of the targets is different than that affected by conventional antibiotics.
[0016] n some embodiments, the DART molecule has a b-lactam ring and a quinolone nucleus, or a quinolone nucleus and a nitro-heterocycle, or a b-lactam ring and a nitroheterocycle
[0017] In some embodiments, the DART has at least two distinct antibacterial mechanisms of action, for example inhibits DNA gyrase or topoisomerase IV and transpeptidase-mediated cross-linking of peptidoglycans; inhibits isoprenyl pyrophosphate and transpeptidase-mediated cross-linking of peptidoglycans; inhibits isoprenyl pyrophosphate and DNA gyrase of topoisomerase IV; inhibits folate synthesis and DNA gyrase of topoisomerase IV; inhibits folate synthesis and transpeptidase-mediated cross-linking of peptidoglycans; inhibits DNA gyrase or topoisomerase IV and the 30S ribosomal sub-unit in bacteria; inhibits DNA gyrase or topoisomerase IV and the 50S subunit in bacteria; inhibits transpeptidase-mediated cross-linking of peptidoglycans and the 30S or the 50S ribosomal sub-unit in bacteria; inhibits folate synthesis and the 30S or the 50S sub-unit in bacteria; or inhibits isoprenyl pyrophosphate and the 3OS or the 50S sub-unit in bacteria, or causes DNA modification, such as inducing DNA nickswhile inhibiting the induction of negative supercoils in DNA;or altering the fluidity of the cell membrane while exerting an activity on the DNA; or altering the levels of metal ions in a cell while inducing DNA changes .in some embodiments, the first mechanism of action is an anti-bacterial action and the second mechanism of action is anti-inflammatory or immunomodulatory
[0018] In some embodiments, the DART molecule has at least two distinct treating acne mechanisms of action and modulates at least two different targets. In some embodiments, the first mechanism is an antibacterial action a d the second mechanism of action is inhibition of keratinocyte proliferation and differentiation n some embodiments, the DART molecule has two distinct acne treating mechanisms of action and whereinthe first mechanism is an antibacterial action and the second mechanism of action is anti-inflammatory. In some embodiments, the DART molecule is effective against forms of Propionbacterium acnes that respond poorly to clindamycin-, or doxycycline-, or erythromycin-, or minoeyeline-eontaining anti-acne products . In some embodiments, they areeffective against one or more of clindamycin-, minocycline-, erythromycin-, and/or doxycycline- tolerant or resistant strains of Propionbacterium acnes. I some embodiments, it prevents the development of resistance in P acnes,
[0019] In some embodiments, the DART molecule has at least two distinct anti-bacterial mechanisms of action and modulates at least two different targets against a pathogen. Non limiting examples of such pathogens are : Bartonella henselae, Borrelia burgdorferi, Campylobacter jejuni, Campylobacterfetus, Chlamydia trachomatis, Chlamydia pneumoniae, Chylamydia psittaci, Simkania negevensis, Escherichia coli (e.g., 0157:H7 and 88), Ehrlichia chafeensis, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Enterococcus faecalis, Haemophilias influenzae, Haemophilius ducreyi, Coccidioides immitis, Bordetella pertussis, Coxiella burnetii, Ureaplasma urealyiicum, Mycoplasma geniialium, Trichomatis vaginalis, Helicobacter pylori, Helicobacter hepaiicus, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium hovis, Mycobacterium africanum, Mycobacterium leprae, Mycobacterium asiaticum, Mycobacterium avium, Mycobacterium celatum, Mycobacterium celonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium haemophilum, Mycobacterium intracellular e, Mycobacterium kansasii, Mycobacterium malmoense, Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium ulcerans, Mycobacterium xenopi, Corynebacterium diptheriae, Rhodococcus equi, Rickettsia aeschlimannii, Rickettsia africae, Rickettsia conorii, Arcanobacterium haemolyticum, Bacillus anthracis, Bacillus cereus, hysteria monocytogenes, Yersinia pestis, Yersinia enterocolitica, Shigella dysenteriae, Neisseria meningitides, Neisseria gonorrhoeae, Streptococcus hovis, Streptococcus hemolyticus, Streptococcus mutans, Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pneumoniae, Staphylococcus saprophyticus, Vibrio cholerae, Vibrio parahaemolyiicus, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Treponema pallidum, Candida, Cryptcooccus, Cryptosporidium, Giardia lamblia, Microsporidia, Plasmodium vivax, Pneumocystis carinii, Toxoplasma gondii, Trichophyton mentagrophytes, Enterocytozoon bieneusi, Cyclospora cayetanensis, Encephalitozoon hellem, Encephalitozoon cuniculi, among other bacteria, archaea, protozoa, and fungi.
[0020] In some embodiments, ihe first and second domains independently have antibacterial activity against a Staphylococcus species. Examples of Staphylococcus species include, but are not limited to, S. aureus group (e.g., S. aureus, S . simiae), S. auricularis group (e.g., S. auricularis), S. carnosus group (e.g., S . carnosus, S. condimenti, S . massiliensis, S. piscifermentans, S. simulans), 5 . epidermidis group (e.g., S. capitis, S. caprae, S. epidermidis, S. saccharolyticus), S. haemolyiicus group (e.g., S . devriesei, S. haemolyticus, S. hominis), S . hyicus-intermedius group (e.g., S. chromogenes, S. felis, S delphini, S. h.yicus, S. intermedius, S. lutrae, S. microti, S. muscae, S. pseudintermedius, S. rostri, S. schleiferi), S. lugdunensis group (e.g., S. lugdunensis), S. saprophytics group (e.g., S. arlettae, S. cohnii, S. equorum, S. gaUlnarum, S. kloosii, S. leei, S. nepalensis, S. saprophytics, S. succinus, S. xylosus), S. sciuri group (e.g., S. jleurettii, S . lentus, S. sciuri, S. stepanovicii, S. vitulinus), S. simulans group (e.g., S. simulans), and S. warneri group (e.g., S. pasteuri, S. warneri).
[0021] Without limitations, the DARTS can be in the form of particles, powders, suspensions, dispersions, emulsions, liposomes, micelles, globules, solutions, vesicles, aggregates, creams, gels, and the like
[0022] The disclosure also provides formulations comprising DARTs as the active pharmaceutical ingredient (API). Antibiotics
[0023] The disclosure also provides formulations comprising antibiotic agents, which are not DARTs, as the API.In some embodiments, the antibiotic agent is a8-chloro fluoroquinolone. Exemplary 8~ehloro fluoroquinolones include, but are not limited to, besifloxacin, clinafloxacin and sitafloxacin. In some embodiments, the formulation comprises besifloxacin as the API.
[0024] In various embodiments, the API can be micronized, suspended, or solubilized. In some embodiments, the API can be in the form of particles, powders, suspensions, dispersions, emulsions, liposomes, micelles, globules, solutions, vesicles, aggregates, and the like. In some embodiments, the API ca in the form of a drug carrier.
[0025] In some embodiments, the API can be coated. In some other embodiments, the API can be uncoated.
[0026] Without limitations, the formulation can be in a form selected from the group consisting of lotions, creams, gels, emulgel, oils, serums, powders, sprays, ointments, solutions, suspensions, dispersions, pastes, foams, peels, films, masks, patches, sticks, rollers, cleansing liquid washes, cleansing solid bars, pastes, foams, powders, shaving creams, impregnated fabric ), and the like. In some I embodiments, the formulation is in a form selected from the group consisting of gel, cream, spary, face wash, soap bar, body wash, lotion., suspended drug loaded gel, suspended drug loaded cream, and any combinations thereof.
[0027] In some embodiments, the API or the formulation can be used to treat acne not responding to antibiotics. Specifically, it exerts greater efficacy against forms of Propionbacterium acnes that respond poorly to clindamycin-, or doxycyc!ine-, or erythromycin-, or minocycline-containing anti-acne products.
[0028] In some embodiments, the API or the formulation can be used to treat acne by exerting an anti-inflammatory effect.
[0029] In some embodiments, the API or the formulation can be used to treat acne by killing strains of Propionbacterium acne that are sensitive toone or more of clindamycin-, minocycline-, erythromycin-, and/or doxycyclineand additionally exerting a greater efficacy by inhibiting P. «e.v-mediated inflammatory pathways (i.e. dual mechanisms of action). Combinations
[0030] The disclosure also provides formulations comprising a combination of two or more antibiotic agents. For example, an 8-chloro fluoroquinolone in combination with another anti-acne agent. In some embodiments, the formulation comprises two or more different 8-chloro fluoroquinolones n some embodiments, the formulation comprises besifloxacin and a retinoid, such as adapalene.
[0031] In some embodiments, the formulation comprises an anti-acne agent and an anti-inflarnmatory agent. For example, the formulation can comprise an 8-chloro fluoroquinolone and an anti-inflammatory agent.
[0032] In some embodiments, the two or more antibiotic agents can be a DART molecule or two or more different DART molecules. In some embodiments, one of the two or more antibiotic agent is a DART and the other is not a DART molecule.
[0033] As described herein, the disclosure provides formulations comprising DART and/or non-DART antibitotic agent as the API. As such, exemplary API's for the formulations include DARTs, anti-bacterial, anti-fungal and anti-acne agents. In some embodiments, the API can be in the form of a drug carrier, i.e., the API can be nanotized, coated, made into vesicles, liposome, emulsions, and the like for the formulation. Without limitations the formulation or the composition can be formulated for administration by any appropriate route known in the art including, but not limited to, topical (including buccal and sublingual) and oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, and nasal administration.
[0034] The DARTs and formulations disclosed herein can be used for treating bacteria! infections due to Gram-positive or Gram-negative bacteria. Additionally, the DARTs are effective against resistant forms of pathogens. Furthermore, the DARTs are effective in preventing the development of resistant forms of pathogens. Thus, the DARTs and formulations disclosed herein can be used for treating antibiotic tolerant or resistant bacterial infections. Exemplary bacterial infections include, but are not limited to, infection by Bartonella henselae, Borrelia burgdorferi, Campylobacter jejuni, Campylobacterjetus, Chlamydia trachomatis, Chlamydia pneumoniae, Chylamydia psittaci, Simkania negevensis, Escherichia coli {e.g., 0157:H7 and K88), Ehrlichia chafeensis, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Enterococcus faecalis, Haemophilius influenzae, Haemophilius ducreyi, Coccidioides immitis, Bordetella pertussis, Coxiella burnetii, Ureaplasma urealyticum, Mycoplasma genitalium, Trichomatis vaginalis, Helicobacter pylori, Helicobacter hepaticus, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium leprae, Mycobacterium asiaticum, Mycobacterium avium, Mycobacterium celatum, Mycobacterium celonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium haemophilum, Mycobacterium intracellular e, Mycobacterium kansasii, Mycobacterium malmoense, Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium ulcerans, Mycobacterium xenopi, Corynebacterium diptheriae, Rhodococcus equi, Rickettsia aeschlimannii, Rickettsia africae, Rickettsia conorii. Arcanobacterium haemolyticum, Bacillus anthracis, Bacillus cereus, hysteria monocytogenes, Yersinia pestis, Yersinia enterocoliiica, Shigella dysenteriae, Neisseria meningitides, Neisseria gonorrhoeae, Streptococcus hovis, Streptococcus hemolyticus, Streptococcus mutans, Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pneumoniae, Staphylococcus saprophyticus, Vibrio cholerae, Vibrio parahaemolyticus, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Treponema pallidum, Candida, Cryptcooccus, Cryptosporidium, Giardia lamhlia, Microsporidia, Plasmodium vivax, Pneumocystis carinii', Toxoplasma gondii, Trichophyton mentagrophytes, Enter ocyiozoon bieneusi. Cyclospora cayetanensi's, Encephalitozoon hellem, Encephalitozoon cimiculi, among other bacteria, archaea, protozoa, and fungi. In some embodiments, infection is with a Staphylococcus species.
[0035] n some embodiments, the DARTS and formulations disclosed herein ca be used for treating acne. In some embodiments, the DARTS and formulations disclosed herein are effective against forms of Propionbacterium acnes that respond poorly to clindamycin-, or doxycycline-, or erythromycin-, or rnmocyciine-eontammg anti-acne products. In some embodiments, the DARTs and formulations disclosed herein are effective against one or more of clindamycin-, minocycline-, erythromycin-, and/or doxycycline- tolerant or resistant strains of Propionbacterium acnes. For treating infections, the DART or the formulation disclosed herein can be administered once or daily to the subject as a single dose or a plurality of doses. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figs 1A a d B shows dose response curves of different antibiotics against both MTCC1951 and CCARM 9010 strains of P. acnes. While MTCC1951 is killed by clindamycin, the drug has no effect on CCARM9010. Different antibiotics behave differently and unpredictably on the different strains belong to a different family from Clindamycin.
[0037] Figs, 1C and D are line graphs showing concentration efficacy curve of DART compounds 90, 91, 94, 113, 115 a d 116 in both clindamycinsusceptible (MTCC 1951) (Fig. 1C) and clindamycin-nonresponsive (CCARM 9010) (Fig ID) P. acnes strains. The molecules have different and unpredictable activity against MTCC 1951 and CCARM9010 strains of P. acnes. Compound 9 1 showed highly efficacious bacterial killing profile for both bacterial strains. Compound 90 shows activity in P. acnes that do not respond to clindamycin but is ineffective in the P. acnes strain that responds to clindamycin.
[0038] Figs, 2A a d 2 show concentration-dependent inhibition of DNA gyrase activity (super-coiling) by compound 91. Fig. 2A - Agarose gel electrophoresis showing effect of compound 9 1 on super-coiling of E. coli p as id DNA by DNA Gyrase. Fig. 2B -Percentage of DNA super-coiling by DNA gyrase in presence increasing concentrations of compound 91.
[0039] Figs. 3A is a bar graph showing percentage of DNA super-coiling by DNA gyrase in presence of compounds 90, 91, 94, 113, 115 and 116 with relaxed E. coli plasmid DNA Compound 9land compound 1 6 seemed to have the best gyrase inhibiting activity among al the comparators. Though this observation is mostly correlated with MIC data agianst P. acnes, yet there is some speciesspecific advantages is observed with compound 91.
[0040] Fig. 3B is a bar graph showing percentage of DNA super-coiling by DNA gyrase in presence of compound 9 1 and nadifloxacin with relaxed E. coli plasmid DNA. Compound 9 1 showsgreaterefficacy than Nadifloxacin.
[0041] Figs. 4A a d 4B are bar graphs showing the effect of compound 9 1 on P. c -induced cytokine L - 6 (Fig. 4A), L - 8 (Fig. 4B) release in THP-1 cells. Compound 9 1 exerts an anti-inflammatory activity against P. c e -induced cytokine production. Statistical analysis was performed using Student's West (* p = 0.05; ** p = 0.005).
[0042] Figs. 5A a d 5B are bar graphs showing the effect of compound 91 on P c -induced cytokine IL - l a (Fig. 5A), IL - 1 (Fig. SB) release in THP-1 cells.
[0043] Fig, 6, is a bar graph showing the minimum inhibition value for some exemplary topical gel formulations against P. acnes.
[0044] Fig, 7 is a line graph showing the dose response curve of Zone of inhibition (ZOI) of some exemplary ge formulations against P. acnes.
[0045] Fig, 8 is a line graph showing the time kill kinetics of some exemplary gel formulations against P. acnes.
[0046] Fig, 9 Graph shows the efficacy of a topical formulation of besifloxacin in P. acnes in an in vivo skin infection model. Besifloxacin gel formulation has the ability to clear almost 1.5 log CFU (-95%) of inoculum of clindamycin resistant P. acnes within first 24 hours. .
[0047] Fig. 10 is a line graph showing time kill kinetics of some exemplary besifloxacin formulations against P. acnes MTCC 1951, showing that the composition of the formulation can change the efficacy of an antibiotic.
[0048] Fig. His a line graph showing time kill kinetics of some exemplary besifloxacin formulations and besifloxacin AP s against S. aureus.
[0049] Fig. 12 is a line graph showing time kill kinetics of besifloxacin against P. acnes (CCARM 90 0)
[0050] Fig. 13 Graph shows that topical formulations with different excipient compositions for the same antibiotic can result in different profiles in the skin and in systemic circulation of SD rats. Fully suspended 1% Besifloxacin ge (VLNF19/ BSF/GL/068), fully soluble 1% Besifloxacin gel (VLN-F21/BSF/GL/001A) and fully suspended 1% Besifloxacin gel (VLN-F20/BSF/CR/004) were used for comparison purpose. To be efficacious, a formulation should not only be physicochemically compatible with the antibiotic but also enable a sustained concentration of the antibiotic at a concentration greater than M C level.
[0051] Figs 14A and 14 are bar graphs showing the concentrationdependent inhibitory effect of Besifloxacin on P. c ei -induced cytokines IL-6 (Fig. 14A) but not IL-8 (Fig. 14B) release in THP-1 cells. Statistical analysis was performed using Student's /-test (* p = 0.005; ** p = 0.0005).
[0052] Figs. SA a d 15B are bar graph showing the combination of Besifloxacin and Adapalene increases the efficacy of inhibiting P. acnes-induced cytokines IL-6 (Fig, SA) but has no effect on IL-8 (Fig. 15B) release in THP-1 cells. Statistical analysis was performed using Student's est (* p = 0 005; ** r = 0.001). DETAILED DESCRIPTION OF THE INVENTION
[0053] Acne vulgaris is a skin condition that affects over 85% of a l people. Acne is a term for a medical condition of plugged pores typically occurring on the face, neck, and upper torso. Following are four primary factors that are currently known to contribute to the formation of acne vulgaris; (1) increased sebum output resulting in oily, greasy skin; (2) increased bacterial activity, normally due to an overabundance of Propionibacterium acnes bacteria; (3) plugging (hypercornification) of the follicle or pilosebaceous duct; and (4) and inflammation. The plugged pores result in blackheads, whiteheads, pimples or deeper lumps such as cysts or nodules. Severe cases of acne can result in permanent scarring or disfiguring.
[0054] As articulated in http://thescienceofacne.com antibiotic-susceptibilitvof-propionibacterium-acnes/ results from studies over last four decades clearly demonstrate that over time P. acnes bacteria has become increasingly resistant to certain classes of antibiotics.Particularly important are observations that a significant percentage of the bacteria isolated from acne patients are now resistant to the most common antibiotics used in acne treatment: Clindamycin, Erythromycin, Tetracycline, Doxycycline and Minocycline. Additionally, such resistant or antibiotic-tolerant strains can cause relapse of acne, and also cause other diease states. There is a need for antibiotics that can kill P. acnes while minimizing the probability of development of mutant or tolerant strains that can survive the antibiotic exposure, and those that can work against strains that are not responding to the current drugs. Additionally, if these novel molecules can target additional steps in acne formation, such as inflammation, then the clinical outcome in acne can be greater than existing therapies.
[0055] Skin is a major organ of the body, and performs many essential functions besides acting as a barrier, such as maintaining homeostasis. Besides acne, there are many other skin diseases that are caused by bacterial colonization of the skin. The most common bacteria for mild to moderate skin infection are Staphylococcus and Streptococcus e.g., Acute Bacterial Skin and Skin Structure infection (ABSSSI). Such bacteria can infect the skin of both pediatric and adult patients; mainly develop during hospitalization or living in a nursing home, while gardening, or while swimming. Some people are at particular risk of developing skin infections, for example, people suffering with diabetes, human immunodeficiency virus (HIV) or AIDS or other immune disorders, or hepatitis, and who is undergoing chemotherapy or treatment with other drugs that suppress the immune system.
[0056] Common skin bacterial infections include cellulitis, erysipelas, impetigo, folliculitis, and furuncles and carbuncles. Cellulitis is a painful, erythematous infection of the dermis and subcutaneous tissue characterized by warmth, edema, and advancing borders and is usually caused by Streptococcus or Staphylococcus species. Erysipelas is a superficial form of cellulitis with sharply demarcated borders and is caused almost exclusively by Streptococcus. Impetigo is also caused by Streptococcus or Staphylococcus and can lead to lifting of the stratum comeum resulting in the commonly seen bullous effect. Folliculitis is an inflammation of the hair follicles, and it is most commonly caused by Staphylococcus. If the infection of the follicle is deeper and involves more follicles, it moves into the furuncle and carbuncle stages and usually requires incision and drainage. Two different kinds of skin diseases occurred due to the toxins produced by the bacteria include, Staphylococcal Scaled Skin Syndrome (SSSS) which usually affects children less than 5 years old, adults with kidney failure and the other one is Toxic Shock Syndrome.There is more chance of colonization of S. aureus is found with patients suffering from eczema and atopic dermatitis, a type of inflammatory, relapsing, non-contagious, itchy skin disorder. Thus Staphylococcus aureus infection plays an important ro e in atopic dermatitis (AD) or atopic eczema (AE). Unfortunately, some strains of Staphylococcus have become resistant to methicillin and other similar antibiotics which are known as MRSA. Recently it has been found that more than one-half of all cases of skin bacterial infections caused by MRSA species. The infections associated with MRSA species cannot be cured with traditional penicillin-related drugs. Instead, MRSA must be treated with alternate antibiotics. [0057 However as articulated in http://thescienceofacne.com/antibioticsuscept'ibi ¾ity-of-propionibacterium-acnes/ "Not all antibiotics are created equal". The same is true for bacteria. Some types of antibiotics are highly effective against certain types of bacteria, while essentially worthless against others. Moreover, antibioitic susceptibility and resistance is a dynamic process that is constantly changing. Over time, certain types of bacteria may gain or lose resistance to particular antibiotics. The primary problem with standard, laboratory-based antibiotic resistance testing is that the susceptibility of a bacteria to an antibiotic is often different when it is growing on a petri dish versus when it is growing on your body. This is because bacteria are not static organisms, they adapt to their environment. A P. acnes bacteria growing in a follicle and feeding on sebum has a different metabolic profile than one growing on a petri dish and feeding on a bacterial nutrition supplement. Furthermore, bacteria modulate expression of surface proteins, eel! wall structures and genesdepending on their environment, and these changes can have a profound effect on their susceptibility to a particular antibiotic. As a result, in the case of topical antibiotics for treatment of skin bacterial conditions, apriori knowledge does not exist, i.e. there is no mechanism to predict that an antibiotic will be effective against P. acnesacnes or any other skin bacterial condition until it has been tested on the bacterial strain. For example, as shown in http://thescienceofacne.corri/antibiotic-susceptibilitv-ofpropionibacterium-acnes/ , P. acnes was reported to be highly resistant to a nitroiniidazole (metronidazole) or a tetracycline (lymecycline) but partially responsive to doxycycline (another tetracycline), and showing no resistance to ciprofloxacin but resistant to another fluoroquinolone, Levofloxacin.lt is therefore impossible to predict which antibiotic will work based on a priori activity in other bacterial strains. There is a need for a systematic development of novel antibiotics that show activity against acne.
[0058] In this regard DART molecules can act as an ideal drug candidate to acne caused by P. acnes, and additionally for the treatment of other skin and skin structure infections caused by other bacteria such as MRSA. DARTs were designed to contain two distinct chemical domains, selected from different families as mentioned earlier, for example a b-lactam ring and a quinolone nucleus, or a quinolone nuclues and nitro-heterocyele, or a b-lactarn ring and a nitroheterocycle, which confers two distinct mechanisms of action. This creates less chance in mutation development at both target sites of bacteria resulting in less resistance development against these antibiotics. Some of the molecules can exert additional anti-inflammatory mechanisms to reduce host inflammatory response, further enhancing the anti-acne efficacy.
[0059] The embodiments of the various aspects disclosed herein are based on the molecules designed by the inventors, which can act on at least two different or distinct targets. Generally, the molecule includes at least two different or distinct chemical domains. Each of said chemical domains binds to a distinct or different active site in a target cell. The said chemical domains can be bound together through a third domain. As used herein, the term "chemical domain" means a part of a molecule that is involved in a desired property. For example, a chemical domain can be part of the molecule involved in binding of the molecule with a target or involved in modulating an activity of the target.
REFERENCES * Jeremy et al (2003). Journal of Investigative Dermatology; 12 : 20-27; ® Thibout et al (2014). Journal of Investigative Dermatology; 134: 307-310; * Tagiietti e al (2008) Skin Therapy Letter. 2008; 13(5): 6-8; Regoes et al. (2004) Antimicrob Agents Chemother:48(10): 3670-6; * Miller et al. (2004) Science;305 (5690): 629-3 1; * Keren et al. (2004) J. Bacterid; 186: 8172-8180; * Schulzen e al. (2001), Nature 4 3: 814-821; * Beitru et al. (2003) Antimicrob Agents Chemother.; 47(3): 1 12-1 4; ® Cambau et al. (2009). Antimicrob. Chemother.63 (3): 443-450; * Kim et al. (2002) Journal of immunology; 169(3): 1535-41; * Liu et al.(2005) Journal of Immunology; 174(5): 2467-2470; * Nagy et al.(2006) Microbes infect; 8(8): 2 195-205; * Lee et al. (2010) Arch Dermatol Res; 302(10): 745-56; * Mouser et a . (2003) J nvest Dermatol; 121(5): 1226-8; * Zasloff et a (2002) Nature; 415: 389-395; ® Epand et al. (1999) Biochim Biophys Acta: 1 62: 1-28; Kabara e al. (1972) Antimicrobn Agents Chemother; 2(1): 23-28; and * De Lucca et ai. (2000) Rev. Iberoam. Micol; 17: 1 6-120 2 16 The formulation of claim 1, wherein the formulation is formulated for topical, oral or parenteral administration. The formulation of claim 10, wherein the formulation is an oral dosage, injectable, aerosol or inhalant, lotion, cream, gel, emulgel, oil, serum, powder, spray, ointment, solution, suspension, dispersion, paste, foam, peel, films, mask, patch, stick, roller, impregnated fabric, or any combination thereof. The formulation of claim 1, further comprising a second anti-baterial agent. The formulation of claim 12, wherein the second anti-baterial agent t is selected from the group consisting of 8-chloro fluroquinolones, acetretin, adapalene(s), alitretinoin, alpha- or beta-hydroxy acids, antibiotics, antimicrobial peptides, antimicrobials, azelaic acid, benzoyl peroxide, bexarotene, bile salts, biofilm inhibitors, clindamycin, erythromycin, etretinate, glycolic acid, isotretinoin, keratolytic agents, lactic acid, lipoic acid, N-acetylcystein, natural anti-acne agents, octopirox, phenoxyethanol, phenoxypropanol, pyruvic acid, resorcinol, retinoic acid, retinoid(s), salicylic acid, sebostats, sodium sulfacetamide, spironolactone, sulfur, sulfur containing D- or L-amino acids, tazarotene, tea tree oil, tretinoin, triclosan, urea, and any combinations thereof. The formulation of claim 1, wherein the formulation comprises an 8-chloro fluoroquinolone alone or in combination with a second anti-baterial agent. The formulation of claim 14, wherein the formulation comprises besifloxacin and adapalene. The formulation of claim 14, wherein the formulation comprises 8-chlorofluoroquinolone and an anti-inflammatory agent. The formulation of claim 16, wherein the formulation comprises 8-chlorofluoroquinolone and retinoic acid or retinoid. The formulation of claim 12, wherein the first or the second anti-bacterial agent is in the form of a drug carrier comprising the said first or second anti-bacterial agent and at least one additional compound, said additional compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of claim 8, wherein the second anti-bacterial agent drug carrier has a size of about 5 nm to about 50 m h. 218 The formulation of claim 19, wherein the second anti-bacterial agent drug carrier has a size of about 100 nm to about 25 mpi The formulation of claim 18, whereinthe second anti-bacterial agent drug carrier comprises a surface modifier on the surface thereof. The formulation of claim 19, wherein the surface modifier of the second anti¬ acne agent drug carrier is selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of claim 18, wherein the surface of the second anti-bacterial agent drug carrier is substantially free of surface modifier. The formulation of claim 1, further comprising an additional active agent. The formulation of claim 24, wherein the additional active agent is an antiinflammatory-agent, penetration enhancer, anti-oxidant, anti-aging agent, antiwrinkle agent, skin whitening or bleaching agent, ultraviolet (UV) light absorbing or scattering agent, skin depigmentation agent, skin regenerative agent, scar healing agent, or any combination thereof The formulation of claim 24, wherein the additional active agent is in the form of a drug carrier comprising a compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of claim 26, wherein the additional active agent drug carrier has a size of about 5 nm to about 100 mh . The formulation of claim 27, wherein the additional active agent drug carrier has a size of about 100 nm to about 25 m h . The formulation of claim 24, whereinthe additional active agent drug carrier comprises a surface modifier on the surface thereof. The formulation of claim 29, wherein the surface modifier of the additional active agent drug carrier is selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of claim 24, wherein the surface of the additional active agent drug carrier is substantially free of surface modifier. The formulation of claim 1, wherein the formulation further comprises a zinc compound. 219 33. The formulation of claim 33, wherein the formulation comprises a moisturizing agent, humectant and /or emolient. 34. The formulation of claim 1, wherein the formulation comprises an antibiotic in soluble form. 35. The fomulation as claimed in any preceding claim having the following composiiton: 36. Use of 8-chloro fluoroquinolone for the treatment of acne, particularly, drug resistant acne. 37. Use of 8-chloro fluoroquinolone for the preparation of medicament for the treatment of acne, particularly, drug resistant acne. 38. Use of besifloxacin for the treatment of acne, particularly, drug-resistant acne. 39. Use of besifloxacin for the treatment of acne via resolution of inflammation. 220 Use of besifloxacin, either alone or in combination with another active for the preparation of medicament for the treatment of acne, particularly, drug-resistant acne. A method for treatment of acne, which comprises administering to a patient in need thereof an effective amount of a formulation as claimed in any one of claims 1 to 35. A method for treatment of acne, particularly where P acne is present and is not responding to a therapeutic dose of clindamycin, minocycline, tetracycline and erythromycin, which comprises administering to a patient in need thereof an effective amount of a formulation as claimed in any one of claims 1 to 35. A Dual Action Rational Therapeutic (DART) molecule that has two distinct mechanisms of action for treatment or prevention of bacterial infections. A Dual Action Rational Therapeutic (DART) molecule of claim 43 that has two distinct anti-bacterial mechanisms of action or an anti-bacterial and an anti-inflammatory action. The molecule of claim 43, wherein the molecule inhibits DNA gyrase or topoisomerase IV and transpeptidase-mediated cross-linking of peptidoglycans. The molecule of claim 43, wherein the molecule inhibits isoprenyl pyrophosphate and transpeptidase-mediated cross-linking of peptidoglycans. The molecule of claim 43, wherein the molecule inhibits isoprenyl pyrophosphate and DNA gyrase of topoisomerase IV. The molecule of claim 43, wherein the molecule inhibits folate synthesis and DNA gyrase of topoisomerase IV. The molecule of claim 43, wherein the molecule inhibits folate synthesis and transpeptidase-mediated cross-linking of peptidoglycans. The molecule of claim 43, wherein the molecule inhibits DNA gyrase or topoisomerase IV and the 30S sub-unit in bacteria. The molecule of claim 43, wherein the molecule inhibits DNA gyrase or topoisomerase IV and the 50S sub-unit in bacteria. The molecule of claim 43, wherein the molecule inhibits transpeptidase-mediated cross-linking of peptidoglycans and the 30S or the 50S sub-unit in bacteria. The molecule of claim 43, wherein the molecule inhibits folate synthesis and the 30S or the 50S sub-unit in bacteria. 221 The molecule of claim 43, wherein the molecule inhibits isoprenyl pyrophosphate and the 30S or the 50S sub-unit in bacteria. The molecule of claim 43, wherein the molecule exerts an antimicrobial activity via the generation of toxic intermediates and/or free radicals while additionally inhibiting DNA gyrase and/or topoisomerase. A Dual Action Rational Therapeutic (DART) molecule that has two distinct anti¬ acne mechanisms of action. The molecule of claim 56, wherein the molecule modulates at least two different targets in acne. The molecule of claim 56, wherein the molecule modulates at least two different targets in P. acnes. The molecule of claim 56, wherein the first mechanism is an antibacterial action and the second mechanism of action is inhibition of keratinocyte proliferation and differentiation. The molecule of claim 56, wherein the first mechanism is an antibacterial action and the second mechanism of action is anti-inflammatory. A Dual Action Rational Therapeutic (DART) molecule which comprises a quinolone and a nitro-heterocycle. A Dual Action Rational Therapeutic (DART) molecule that comprises a betalactam and a nitro-heterocycle. A Dual Action Rational Therapeutic (DART) molecule that comprises a betalactam and a quinolone. A Dual Action Rational Therapeutic (DART) molecule which includes two chemical domains, each said chemical domain binding to a distinct active site in target cells, wherein said chemical domains are bound together through a third domain. The molecule of claim 64, wherein the third domain is a linker. The molecule of claim 64, wherein the third domain is a cleavable linker. The molecule of claim 64, wherein the third domain is a non-cleavable linker. The molecule of claim 64, wherein said third domain is 11-hydroxyundecenic acid; 1,10-decanediol; 1,3 -propanediol; 1,5-pentanedil; 10-hydroxydecenic acid; succinic; lactic acid; 3-hydroxypropionic acid; or any combination thereof.. The molecule of claim 64, wherein the third domain increases an activity of at least one of the two chemical domains. 222 The molecule of claim 64, wherein the third domain has antibacterial or anti¬ inflammatory activity. The molecule of any of claims 43-70, wherein the molecule is in the form of a drug carrier. The molecule of any of claims 43-70, wherein the molecule is in solubilized form. The molecule of claim 71, wherein the drug carrier has a size of about 5 m to about 100 m The molecule of claim 71, wherein the drug carrier has a size of about 100 n to about 25 m . The molecule of claim 71, wherein the drug carrier further comprises a compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The molecule of claim 71, wherein the drug carrier further comprises an additional active agent. The molecule of claim 71, wherein the additional active agent is an antiinflammatory-agent, keratolytic agent, penetration enhancer, anti-oxidant, antiaging agent, anti-wrinkle agent, skin whitening or bleaching agent, ultraviolet (UV) light absorbing or scattering agent, skin depigmentation agent, skin regenerative agent, scar healing agent, or any combination thereof. The molecule of claim 71, wherein surface of the drug carrier is substantially free of surface modifier. The molecule of claim 71, wherein the drug carrier further comprises an additional anti-acne agent. The molecule of claim 79, wherein the second anti-acne agent is selected from the group consisting of acetretin, adapalene(s), alitretinoin, alpha- or betahydroxy acids, antibiotics, antimicrobial peptides, antimicrobials, azelaic acid, benzoyl peroxide, bexarotene, bile salts, biofilm inhibitors, clindamycin, erythromycin, etretinate, glycolic acid, isotretinoin, keratolytic agents, lactic acid, lipoic acid, N-acetylcystein, natural anti-acne agents, octopirox, phenoxyethanol, phenoxypropanol, pyruvic acid, resorcinol, retinoic acid, retinoid(s), salicylic acid, sebostats, sodium sulfacetamide, spironolactone, sulfur, sulfur containing 223 D- or L-amino acids, tazarotene, tea tree oil, tretinoin, triclosan, urea, and any combinations thereof. 81. The molecule of claim 71, wherein the drug carrier further comprises a surface modifier on the surface thereof. 82. The molecule of claim 81, wherein the surface modifier is a compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combination thereof. 83 A DART molecule as re resented by the structure: DART 90 84. A DART molecule as represented by the structure: DART 9 1 85 A DART molecule as represented by the structure: DART 115 224 A DART molecule as represented by the structure: DART 116 The molecule as claimed in any one of the claims 43-82 is selected from structures shown in claims 83-86 The formulation comprising a dual action rational therapeutic molecule of any of claims 43-87 and at least one carrier or excipient. The formulation of claim 88, wherein the carrier or excipient is selected from the group consisting of emulsifiers, preservatives, surfactants, oils, lipids, waxes, stabilizers, rheology modifiers or thickening agents (gelling agent), emollients, moisturizers, conditioning agents, fragrances/perfumes, potentiating agents, preservatives, opacifiers, antioxidants, cooling agents, film forming agents, abrasives, exfoliating agents, colorants, pH modifiers, solvents, vehicle, penetration enhancers, permeation enhancers, pearlizing agents, and any combinations thereof. The formulation of claim 88 comprising from about 5% to about 99% (w/w or w/v) of the carrier or excipient. The formulation of claim 88, wherein the formulation is formulated for topical, oral or parenteral administration. The formulation of claim 88, wherein the formulation is an oral dosage, injectable, aerosol or inhalant, lotion, cream, gel, emulgel, oil, serum, powder, spray, ointment, solution, suspension, dispersion, paste, foam, peel, films, mask, patch, stick, roller, impregnated fabric, or any combination thereof. The formulation of claim 88 further comprising a second anti-acne agent. The formulation of claim 91, wherein the second anti-acne agent is selected from the group consisting of acetretin, adapalene(s), alitretinoin, alpha- or betahydroxy acids, antibiotics, antimicrobial peptides, antimicrobials, azelaic acid, benzoyl peroxide, bexarotene, bile salts, biofilm inhibitors, clindamycin, erythromycin, etretinate, glycolic acid, isotretinoin, keratolytic agents, lactic acid, lipoic acid, N-acetylcystein, natural anti-acne agents, octopirox, phenoxyethanol, 225 phenoxypropanol, pyruvic acid, resorcinol, retinoic acid, retinoid(s), salicylic acid, sebostats, sodium sulfacetamide, spironolactone, sulfur, sulfur containing D- or L-amino acids, tazarotene, tea tree oil, tretinoin, triclosan, urea, and any combinations thereof. 95. The formulation of claim 91, wherein the second anti-acne agent is in the form of a drug carrier. 96. The formulation of claim 93, wherein the second anti-acne agent drug carrier further comprises a compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. 97. The formulation of claim 93, wherein the second anti-acne agent drug carrier has a size of about 5 nm to about 100 m h . 98. The formulation of claim 95, wherein the second anti-acne agent drug carrier has a size of about 100 nm to about 25 m h. 99. The formulation of claim 93, wherein the second anti-acne agent drug carrier comprises a surface modifier on the surface thereof. 100. The formulation of claim 97, herein the surface modifier of the second anti-acne agent drug carrier is selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. 101. The formulation of claim 93, wherein surface of the second anti-acne agent is substantially free of surface modifier. 02. The formulation of claim 88 further comprising an additional active agent. 103. The formulation of claim 100, wherein the additional active agent is an antiinflammatory-agent, penetration enhancer, anti-oxidant, anti-aging agent, antiwrinkle agent, skin whitening or bleaching agent, ultraviolet (UV) light absorbing or scattering agent, skin depigmentation agent, skin regenerative agent, scar healing agent, or any combination thereof. 104. The formulation of claim 100, wherein the additional active agent is in the form of a drug carrier. 105. The formulation of claim 102, wherein the additional active agent drug carrier further comprises a compound selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. 226 A formulation for use in the treatment or prevention of acne, including drugresistant acne and P.acne not responding to/tolerant to a therapeutic dose of clindamycin, minocycline, tetracycline or erythromycin, comprising an anti bacterial agent and at least one additional compound, selected from a carrier, excipient lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of claim 1, wherein the drug carrier comprises the said anti¬ bacterial agent uncoated or coated at least partially with said additional compound. The formulation of claim 2, wherein the anti-baterial agent has a size of about 5 nm to about 20 m . The formulation of claim 3, wherein the drug carrier has a size of about 50 nm to about 10 m . The formulation of claim 1 further comprising a surface modifier on the surface of the anti-baterial agent. The formulation of claim 5, wherein the surface modifier is selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. The formulation of any of claims 1-6, wherein the carrier or excipient is selected from the group consisting of emulsifiers, preservatives, surfactants, oils, lipids, waxes, stabilizers, rheology modifiers or thickening agents (gelling agent), emollients, moisturizers, conditioning agents, fragrances/perfumes, potentiating agents, preservatives, opacifiers, antioxidants, cooling agents, film forming agents, abrasives, exfoliating agents, colorants, pH modifiers, solvents, vehicle, penetration enhancers, pearlizing agents, and any combinations thereof. The formulation of claim 1, wherein the surface of the anti-baterial agent is substantially free of surface modifier. The formulation of claim 1, comprising from about 0.1% to about 50% (w/w or w/v) of the carrier or excipient. 217 106. The formulation of claim 102, wherein the additional active agent drug carrier has a size of about 5 n to about 00 m . 107. The formulation of claim 104, wherein the additional active agent drug carrier has a size of about 00 nm to about 25 m . 108. The formulation of claim 102, wherein the additional active agent drug carrier comprises a surface modifier on the surface thereof. 109. The formulation of claim 106, wherein the surface modifier of the additional active agent drug carrier is selected from the group consisting of lipids, oils, polymers, peptides, proteins, carbohydrates, glycolipids, phospholipids, lipoproteins, cationic molecules, and any combinations thereof. 110. The formulation of claim 102, wherein surface of the additional active agent drug carrier is substantially free of surface modifier. 11 . The formulation of claim 88, wherein the formulation further comprises a zinc compound. 112. A formulation comprising a dual action rational therapeutic molecule claimed in any of claims 83-86 and at least one carrier or excipient. 113. A formulation comprising a dual action rational therapeutic molecule claimed in any of claims 83-86 and at least one carrier or excipient for topical application. 114. A formulation comprising a dual action rational therapeutic molecule claimed in any of claims 83-86 and at least one carrier or excipient for topical application on skin. 115. Use of Dual Action Rational Therapeutic (DART) molecule for the treatment of acne. 116. Use of Dual Action Rational Therapeutic (DART) molecule for the treatment drug-resistant acne. 117. Use of Dual Action Rational Therapeutic (DART) molecule for the preparation of medicament for the treatment of acne, particularly, drug-resistant acne. 18. Use of Dual Action Rational Therapeutic (DART) molecule for the treatment of acne, particularly, drug resistant-acne. 119. Use of Dual Action Rational Therapeutic (DART) molecule, either alone or in combination with another active for the preparation of medicament for the treatment of acne, particularly, drug-resistant acne. 120. Use of Dual Action Rational Therapeutic (DART) molecule, either alone or in combination with another active for the preparation of medicament for the 227 treatment of acne, particularly, P. acnes not responding to clindamycin, minocycline, tetracycline and erythromycin-containing treatments. 2 . A method for treatment of acne, particularly, acne not responding to clindamycin, erythromycin, minocycline, doxycycline or tetracycline-containing therapies, which comprises administering to a patient in need thereof an effective amount of a formulation as claimed in any one of claims 88-1 14. 122. The method of any of claim 42 or 121, wherein the acne condition is caused by antibiotic-susceptible bacterial strain. 123. The method of claim 42 or 121, wherein the acne condition is caused by bacteria not responding to therapeutic doses of clindamycin-, erythromycin-, doxycycline- , minocycline- or tetracycline-containing regimens. 124. The method of claim 123, wherein the acne condition is caused by clindamycin-, tetracycline-, minocycline-, doxycycline-, or erythromycin-nonresponder Propionbacterium acnes. 125. The method of claim 123, wherein the acne condition is caused by clindamycin-, tetracycline-, minocycline-, doxycycline-, or erythromycin-tolerant Propionbacterium acnes. 126. A method of treating a bacterial infection in a subject comprising administering a therapeutically effective amount of a formulation of any of claims 1-35 and 88- 114. 127. The method of claim 126, wherein the infection is caused by a pathogen selected from the group consisting of Bartonella henselae, Borrelia burgdorferi, Campylobacter jejuni, Campylobacterfetus, Chlamydia trachomatis, Chlamydia pneumoniae, Chylamydia psittaci, Simkania negevensis, Escherichia coli (e.g., 0157:H7 and K88), Ehrlichia chafeensis, Clostridium botulinum, Clostridium perjringens, Clostridium tetani, Enterococcus faecalis, Haemophilius influenzae, Haemophilius ducreyi, Coccidioides immitis, Bordetella pertussis, Coxiella burnetii, Ureaplasma urealyticum, Mycoplasma genitalium, Trichomatis vaginalis, Helicobacter pylori, Helicobacter hepaticus, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium ajricanum, Mycobacterium leprae, Mycobacterium asiaticum, Mycobacterium avium, Mycobacterium celatum, Mycobacterium celonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium haemophilum, Mycobacterium intracellulare, Mycobacterium kansasii, Mycobacterium malmoense, 228 Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium ulcerans, Mycobacterium xenopi, Corynebacterium diptheriae, Rhodococcus equi, Rickettsia aeschlimannii,